Kuur Therapeutics

Kuur Therapeutics

Kuur Therapeutics

Date Founded



1 Canal Side Studios,8-14 St Pancras Way,London, Greater London NW1 0QG

Type of Company



Wholesale: Consumer Non-Durables/Sundries
Holding Companies

Company Description

Cell Medica Ltd. provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Kuur Therapeutics? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Scientific Officer

Senior Vice President & Head of Manufacturing Operations

Head of Commercial Operations

Chief Operating Officer

Chief Medical Officer

Senior Vice President-Development

Board of Directors

Executive Chairman at Cocoon Biotech, Inc.

Managing Partner, Life Sciences at IP Group Plc

Managing Director at M.M. Dillon & Co. Group

President & Director at Haemosan, Inc.

Former Senior Vice President at MedImmune Ltd.

Co-Founder at Apposite Capital LLP

Paths to Kuur Therapeutics
Potential Connections via
Relationship Science
Kuur Therapeutics
Recent Transactions
Details Hidden

Kuur Therapeutics purchases Catapult Therapy TCR Ltd. from IP2IPO Innovations Ltd., UCL Business Plc, Cell Therapy Catapult Ltd.

Details Hidden

Touchstone Innovations Investment Management Ltd., Kuur Therapeutics purchase Cell Medica Switzerland from SV Health Investors LLP, HBM Partners AG, VI Partners AG, Clarus Ventures LLC, BioMedPartners AG

Advisors & Consultants
Legal Advisor

Counsel at Davis Polk & Wardwell LLP


Founder at Kuur Therapeutics

Details Hidden

IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team.The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independenceIIIM works toward exits through trade sales, mergers or IPOs.

Details Hidden

Woodford invests in a broad range of sectors and industries. It participates in early stage capital requirements.

Details Hidden

Invesco Perpetual constructs portfolios based on in-house research aiming to identify the investment opportunities most likely to provide the strongest long-term returns. They believe that shareholder activism is fundamental to good corporate governance and while they do not intervene in daily management decisions, they do support general standards for corporate activity and, where necessary, take the initiative to ensure those standards are met. They aim at protecting and enhancing value for clients and investors. The firm's fund managers seek to establish a dialogue with company management to promote decision-making which is in the best interests of shareholders and is in accordance with good corporate governance principles including environmental, social and governance matters. Their UK equity team follows a self-described pragmatic approach with no style bias regarding sectors, stocks or market-cap. Their valuation-orientated approach focuses on absolute returns and risk, allowing the portfolio to capture opportunities over time. In addition to high alpha UK equity, the team also manages small-cap equity and benchmark-relative portfolios. Invesco Perpetual 's European equity team follows a flexible, pragmatic approach focused on delivering consistent outperformance against both the index and the peer group. Fundamental analysis and valuation are central to the investment approach, providing a strong investment discipline that ensures that stocks are purchased only when valuations are appropriate. Their fixed-income team manages retail and institutional accounts, combining macro and bottom-up credit analysis to determine investment opportunities.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kuur Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kuur Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Kuur Therapeutics.